Corinne Tillier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Corinne Tillier has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Andre N. Vis
Afdeling Urologie, Amsterdam UMC, Locatie VUmc, Amsterdam, Nederland
4 shared publications - Henk G. van der Poel
Tijdschrift voor Urologie, Bohn Stafleu van Loghum, Houten, Nederland
4 shared publications - Hans Veerman
Department of Urology, Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
3 shared publications - Marinus Jan Hagens
Department of Urology, Netherlands Cancer Institute, 1066 Amsterdam, The Netherlands
3 shared publications Ah Boekhout
Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
2 shared publicationsBm Wollersheim
Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
2 shared publications
Latest Publications
- 21 October 2024
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 32 (11) , 1-9
Surgical and non-surgical predictors of long term erectile function after robot assisted radical prostatectomy
Purpose Robotic-assisted radical prostatectomy (RARP) impairs erectile function (EF) due to the surgical procedure and non-surgical factors. Non-surgical factors may contribute to recovery of erectile function (EFR) after RARP. This study assessed the role of non-surgical factors including physical activity in baseline EF and EFR after prostatectomy. Methods Patient Reported Measure Outcomes questionnaires from patients with localized prostate carcinoma who underwent a RARP with a postoperative follow up (FU) of 3 years. EFR was defined as at least 70% EF recovery of baseline IIEF-EF. Physical activities was defined as no activity at all, once a week and ≥ 2 a week. Results In total 804 patients were included. At baseline, age, lower urinary tract symptoms (LUTS), having a partner and former smoking were significantly associated (p < .001) of EF. Postoperatively, the extent of nerve sparing and baseline EF were strongly associated with EFR (p < .001). Physical activity ≥ 2 a week predicted EF but only beyond 6 months of FU (p = .005, p = .028 and p = .007 at 1, 2 and 3 year FU respectively). Comorbidities, BMI and the use of medications known to affect EF were not predictive of EFR. Conclusions Age, LUTS, having a partner and former smoking were baseline associated with EF prior to RARP. Baseline EF and extent of nerve sparing jointly predicted EFR. Intensive physical activity was an independent predictor of EFR beyond the first year after RARP. Our findings suggests that besides clinical factors, lifestyle may also play a role in recovery of erectile function.
- 21 October 2024
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 32 (11) , 1-9
Surgical and non-surgical predictors of long term erectile function after robot assisted radical prostatectomy
Purpose Robotic-assisted radical prostatectomy (RARP) impairs erectile function (EF) due to the surgical procedure and non-surgical factors. Non-surgical factors may contribute to recovery of erectile function (EFR) after RARP. This study assessed the role of non-surgical factors including physical activity in baseline EF and EFR after prostatectomy. Methods Patient Reported Measure Outcomes questionnaires from patients with localized prostate carcinoma who underwent a RARP with a postoperative follow up (FU) of 3 years. EFR was defined as at least 70% EF recovery of baseline IIEF-EF. Physical activities was defined as no activity at all, once a week and ≥ 2 a week. Results In total 804 patients were included. At baseline, age, lower urinary tract symptoms (LUTS), having a partner and former smoking were significantly associated (p < .001) of EF. Postoperatively, the extent of nerve sparing and baseline EF were strongly associated with EFR (p < .001). Physical activity ≥ 2 a week predicted EF but only beyond 6 months of FU (p = .005, p = .028 and p = .007 at 1, 2 and 3 year FU respectively). Comorbidities, BMI and the use of medications known to affect EF were not predictive of EFR. Conclusions Age, LUTS, having a partner and former smoking were baseline associated with EF prior to RARP. Baseline EF and extent of nerve sparing jointly predicted EFR. Intensive physical activity was an independent predictor of EFR beyond the first year after RARP. Our findings suggests that besides clinical factors, lifestyle may also play a role in recovery of erectile function.
- 9 September 2023
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 41 (11) , 454.e1-454.e8
Patient-reported outcome measures compared to clinician reported outcomes regarding incontinence and erectile dysfunction in localized prostate carcinoma after robot assisted radical prostatectomy: Impact on management
- 9 September 2023
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 41 (11) , 454.e1-454.e8
Patient-reported outcome measures compared to clinician reported outcomes regarding incontinence and erectile dysfunction in localized prostate carcinoma after robot assisted radical prostatectomy: Impact on management
- Open Access
- 28 February 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (3) , 727
Identifying Patients in Whom the Follow-Up Scheme after Robot-Assisted Radical Prostatectomy Could Be Optimized in the First Year after Surgery: Reducing Healthcare Burden
Background: The currently advised follow-up scheme of PSA testing after robot-assisted radical prostatectomy (RARP) is strict and might pose a burden to our healthcare system. We aimed to optimize the 1-year follow-up scheme for patients who undergo RARP. Methods: All patients with histologically-proven prostate cancer (PCa) who underwent RARP between 2018 and August 2022 in the Prostate Cancer Network in the Netherlands were retrospectively evaluated. We excluded patients who underwent salvage RARP and patients who had 0.10 ng/mL at 0–4 months after RARP, whereas biochemical recurrence (BCR) was defined as PSA level >0.2 ng/mL at any time point after RARP. We aimed to identify a group of patients who had a very low risk of BCR at different time points after surgery. Results: Of all 1155 patients, BCP was observed in 151 (13%), of whom 79 (6.8%) had PSA ≥ 0.2 ng/mL. BCR further developed in 51 (4.7%) and 37 (3.4%) patients at 5–8 and 9–12 months after RARP, respectively. In 12 patients, BCR was found at 5–8 months after RARP in the absence of BCP. These patients represented 1.2% (12/1004) of the entire group. In other words, 98.8% (992/1004) of patients who had an unmeasurable PSA level at 0–4 months after RARP also had an unmeasurable PSA level 5–8 months after surgery. Limitations are the retrospective design and incomplete follow-up. Conclusions: Patients with an unmeasurable PSA level at 3–4 months after RARP may not need to be retested until 12 months of follow-up, as almost 100% of patients will not have the biochemically recurrent disease at 5–8 months of follow-up. This will reduce PSA testing substantially at the cost of hardly any missed patients with recurrent disease.
- 28 February 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (3) , 727
Open AccessIdentifying Patients in Whom the Follow-Up Scheme after Robot-Assisted Radical Prostatectomy Could Be Optimized in the First Year after Surgery: Reducing Healthcare Burden
Background: The currently advised follow-up scheme of PSA testing after robot-assisted radical prostatectomy (RARP) is strict and might pose a burden to our healthcare system. We aimed to optimize the 1-year follow-up scheme for patients who undergo RARP. Methods: All patients with histologically-proven prostate cancer (PCa) who underwent RARP between 2018 and August 2022 in the Prostate Cancer Network in the Netherlands were retrospectively evaluated. We excluded patients who underwent salvage RARP and patients who had 0.10 ng/mL at 0–4 months after RARP, whereas biochemical recurrence (BCR) was defined as PSA level >0.2 ng/mL at any time point after RARP. We aimed to identify a group of patients who had a very low risk of BCR at different time points after surgery. Results: Of all 1155 patients, BCP was observed in 151 (13%), of whom 79 (6.8%) had PSA ≥ 0.2 ng/mL. BCR further developed in 51 (4.7%) and 37 (3.4%) patients at 5–8 and 9–12 months after RARP, respectively. In 12 patients, BCR was found at 5–8 months after RARP in the absence of BCP. These patients represented 1.2% (12/1004) of the entire group. In other words, 98.8% (992/1004) of patients who had an unmeasurable PSA level at 0–4 months after RARP also had an unmeasurable PSA level 5–8 months after surgery. Limitations are the retrospective design and incomplete follow-up. Conclusions: Patients with an unmeasurable PSA level at 3–4 months after RARP may not need to be retested until 12 months of follow-up, as almost 100% of patients will not have the biochemically recurrent disease at 5–8 months of follow-up. This will reduce PSA testing substantially at the cost of hardly any missed patients with recurrent disease.
- Open Access
- 16 January 2023
- Published by MDPI AG in Preprints.org
Identifying Patients in Whom the Follow-up Scheme after Robot-assisted Radical Prostatectomy Could be Optimized in the First Year after Surgery: Reducing Healthcare Burden
Background: The currently advised follow-up scheme of PSA-testing after robot-assisted radical prostatectomy (RARP) is strict and might pose a burden to our healthcare system. We aimed to optimize the 1-year follow-up scheme for patients who undergo RARP. Methods: All patients with histologically-proven prostate cancer (PCa) who underwent RARP between 2018 and August 2022 in the Prostate Cancer Network the Netherlands were retrospectively evaluated. We excluded patients who underwent salvage RARP and patients who had 0.10 ng/mL at 0-4 months after RARP, whereas biochemical recurrence (BCR) was defined as PSA-level >0.2 ng/mL at any time point after RARP. We aimed to identify a group of patients who had a very low risk of BCR at different time-points after surgery. Results: Of all 1155 patients, BCP was observed in 151 (13%), of whom 79 (6.8%) had PSA ≥0.2 ng/mL. BCR further developed in 51 (4.7%), and 37 (3.4%) patients at 5-8 and 9-12 months after RARP, respectively. In 12 patients, BCR was found at 5-8 months after RARP in absence of BCP. These patients represented 1.2% (12/1004) of the entire group. In other words, 98.8% (992/1004) of patients who had an unmeasurable PSA-level at 0-4 months after RARP also had unmeasurable PSA-level 5-8 months after surgery. Limitations are the retrospective design and incomplete follow-up. Conclusions: Patients with an unmeasurable PSA-level at 3-4 months after RARP may not need to be retested until 12 months of follow-up as almost 100% of patients will not have biochemically recurrent disease at 5-8 months of follow-up. This will reduce PSA-testing substantially at the costs of hardly any missed patients with recurrent disease.
- 16 January 2023
- Published by MDPI AG in Preprints.org
Open AccessIdentifying Patients in Whom the Follow-up Scheme after Robot-assisted Radical Prostatectomy Could be Optimized in the First Year after Surgery: Reducing Healthcare Burden
Background: The currently advised follow-up scheme of PSA-testing after robot-assisted radical prostatectomy (RARP) is strict and might pose a burden to our healthcare system. We aimed to optimize the 1-year follow-up scheme for patients who undergo RARP. Methods: All patients with histologically-proven prostate cancer (PCa) who underwent RARP between 2018 and August 2022 in the Prostate Cancer Network the Netherlands were retrospectively evaluated. We excluded patients who underwent salvage RARP and patients who had 0.10 ng/mL at 0-4 months after RARP, whereas biochemical recurrence (BCR) was defined as PSA-level >0.2 ng/mL at any time point after RARP. We aimed to identify a group of patients who had a very low risk of BCR at different time-points after surgery. Results: Of all 1155 patients, BCP was observed in 151 (13%), of whom 79 (6.8%) had PSA ≥0.2 ng/mL. BCR further developed in 51 (4.7%), and 37 (3.4%) patients at 5-8 and 9-12 months after RARP, respectively. In 12 patients, BCR was found at 5-8 months after RARP in absence of BCP. These patients represented 1.2% (12/1004) of the entire group. In other words, 98.8% (992/1004) of patients who had an unmeasurable PSA-level at 0-4 months after RARP also had unmeasurable PSA-level 5-8 months after surgery. Limitations are the retrospective design and incomplete follow-up. Conclusions: Patients with an unmeasurable PSA-level at 3-4 months after RARP may not need to be retested until 12 months of follow-up as almost 100% of patients will not have biochemically recurrent disease at 5-8 months of follow-up. This will reduce PSA-testing substantially at the costs of hardly any missed patients with recurrent disease.
- 1 January 2023
- Published by JLE in Bulletin Infirmier du Cancer
- Vol. 23 (2) , 112-115
Revue de presse internationale
- 1 January 2023
- Published by JLE in Bulletin Infirmier du Cancer
- Vol. 23 (2) , 112-115
Revue de presse internationale
- 28 October 2022
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 30 (12) , 10077-10087
Quality of early prostate cancer follow-up care from the patients’ perspective
Purpose To develop optimal cancer survivorship care programs, this study assessed the quality of prostate cancer follow-up care as experienced by patients shortly after completion of primary treatment. Methods We surveyed 402 patients with localized prostate cancer participating in a randomized controlled trial comparing specialist versus primary care–based follow-up. For the current study, we used patient-reported data at the time of the first follow-up visit at the hospital, prior to randomization. We assessed patients’ ratings of the quality of follow-up care using the Assessment of Patient Experiences of Cancer Care survey. This survey includes 13 scales about different aspects of care and an overall rating of care. Multivariable linear regression analysis was used to identify factors associated with perceived follow-up quality. Results Patients reported positive experiences at first follow-up for 9 of 13 scales, with mean (M) scores ranging from 79 to 97 (on a 0–100 response scale). Patients reported most frequently (over 70%) suboptimal care regarding symptom management (84%; M = 44, SD = 37), health promotion (75%; M = 45, SD = 39), and physician’s knowledge about patients’ life (84%; M = 65, SD = 23). Overall, patients’ lower quality of follow-up ratings were associated with younger age, higher education level, having more than one comorbid condition, having undergone primary surgery, and experiencing significant symptoms. Conclusion Patients with prostate cancer are generally positive about their initial, hospital-based follow-up care. However, efforts should be made to improve symptom management, health promotion, and physician’s knowledge about patients’ life. These findings point to areas where prostate cancer follow-up care can be improved.
- 28 October 2022
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 30 (12) , 10077-10087
Quality of early prostate cancer follow-up care from the patients’ perspective
Purpose To develop optimal cancer survivorship care programs, this study assessed the quality of prostate cancer follow-up care as experienced by patients shortly after completion of primary treatment. Methods We surveyed 402 patients with localized prostate cancer participating in a randomized controlled trial comparing specialist versus primary care–based follow-up. For the current study, we used patient-reported data at the time of the first follow-up visit at the hospital, prior to randomization. We assessed patients’ ratings of the quality of follow-up care using the Assessment of Patient Experiences of Cancer Care survey. This survey includes 13 scales about different aspects of care and an overall rating of care. Multivariable linear regression analysis was used to identify factors associated with perceived follow-up quality. Results Patients reported positive experiences at first follow-up for 9 of 13 scales, with mean (M) scores ranging from 79 to 97 (on a 0–100 response scale). Patients reported most frequently (over 70%) suboptimal care regarding symptom management (84%; M = 44, SD = 37), health promotion (75%; M = 45, SD = 39), and physician’s knowledge about patients’ life (84%; M = 65, SD = 23). Overall, patients’ lower quality of follow-up ratings were associated with younger age, higher education level, having more than one comorbid condition, having undergone primary surgery, and experiencing significant symptoms. Conclusion Patients with prostate cancer are generally positive about their initial, hospital-based follow-up care. However, efforts should be made to improve symptom management, health promotion, and physician’s knowledge about patients’ life. These findings point to areas where prostate cancer follow-up care can be improved.
- Open Access
- 8 August 2022
- Published by Springer Nature in Research Square
Patient-Reported Outcome Measures compared to Clinician Reported Outcomes regarding incontinence and erectile dysfunction in localized prostate carcinoma after Robot Assisted Radical Prostatectomy: impact on management
Purpose/ Background: To examine whether a discrepancy between patient reported outcomes (PROs) and clinician reported outcomes (CROs) impacts the management of urinary incontinence (UI) and erectile dysfunction (ED) after robot assisted radical prostatectomy (RARP). Methods: Up to 1 year after RARP, UI and ED recovery of 312 men with localized and locally advanced prostate cancer were assessed using the International Consultation Incontinence Questionnaire Short Form (ICIQ-SF) and the International Index of Erectile Function (IIEF-EF) and CROs by interview. Discrepancies between PROs and CROs were studied in light of treatment offered and management.Results: The ICIQ-SF Score matched with CROs in all sum score categories except in ICIQ sum score 6-12; here the UI was underreported by clinicians in 58% and 59% of patients at 8 and 12 months (p<.001). Furthermore, at 8 and 12 months postoperatively, clinicians underreported UI in 29% and 23% of patients with ICIQ score 13-18 (p<.001). The clinician significantly over-reported the recovery of erectile function (“normal erection”) (p<.001), especially in men with IIEF-EF sum score 6-16. Independently of ICIQ-SF/IIEF-EF scores, discrepancy between PROs and CROs did not affect rate of health care offered to patients. Conclusions: This is to our knowledge the first study that compared the PROs with clinician reported functional outcomes and the impact of discrepancies on the management of side effects of RARP in prostate cancer. Observed discrepancies between the PROs and CROs did not affect offered management and counseling of UI and ED.
- 8 August 2022
- Published by Springer Nature in Research Square
Open AccessPatient-Reported Outcome Measures compared to Clinician Reported Outcomes regarding incontinence and erectile dysfunction in localized prostate carcinoma after Robot Assisted Radical Prostatectomy: impact on management
Purpose/ Background: To examine whether a discrepancy between patient reported outcomes (PROs) and clinician reported outcomes (CROs) impacts the management of urinary incontinence (UI) and erectile dysfunction (ED) after robot assisted radical prostatectomy (RARP). Methods: Up to 1 year after RARP, UI and ED recovery of 312 men with localized and locally advanced prostate cancer were assessed using the International Consultation Incontinence Questionnaire Short Form (ICIQ-SF) and the International Index of Erectile Function (IIEF-EF) and CROs by interview. Discrepancies between PROs and CROs were studied in light of treatment offered and management.Results: The ICIQ-SF Score matched with CROs in all sum score categories except in ICIQ sum score 6-12; here the UI was underreported by clinicians in 58% and 59% of patients at 8 and 12 months (p<.001). Furthermore, at 8 and 12 months postoperatively, clinicians underreported UI in 29% and 23% of patients with ICIQ score 13-18 (p<.001). The clinician significantly over-reported the recovery of erectile function (“normal erection”) (p<.001), especially in men with IIEF-EF sum score 6-16. Independently of ICIQ-SF/IIEF-EF scores, discrepancy between PROs and CROs did not affect rate of health care offered to patients. Conclusions: This is to our knowledge the first study that compared the PROs with clinician reported functional outcomes and the impact of discrepancies on the management of side effects of RARP in prostate cancer. Observed discrepancies between the PROs and CROs did not affect offered management and counseling of UI and ED.
- 1 June 2021
- Published by Elsevier in European Urology
- Vol. 79, S1620
Functional outcomes rather than complications affect quality of life at 6 months after robot-assisted radical prostatectomy
- 1 June 2021
- Published by Elsevier in European Urology
- Vol. 79, S1620
Functional outcomes rather than complications affect quality of life at 6 months after robot-assisted radical prostatectomy
- 18 May 2021
- Published by Wiley in Neurourology and Urodynamics
- Vol. 40 (6) , 1550-1558
Individual risk prediction of urinary incontinence after prostatectomy and impact on treatment choice in patients with localized prostate cancer
Aims: Individualized information about the risk of incontinence after prostatectomy could help patients in shared decision‐making.Methods: We compared a historical control cohort (n = 254; between June 2016 and 2017) that received standardized information about the risk of incontinence after robot‐assisted radical prostatectomy (RARP) with a prospective patient cohort (n = 254; between June 2017 and May 2018) that received individualized information of the chance of recovery of incontinence within 6 months postoperatively based on the continence prediction tool (CPRED). We measured switch in treatment choice, health‐related quality of life (QoL) in both cohorts and the accuracy of the CPRED tool.Results: Patients in the individualized information group with RARP as initial preference switched more often to another treatment than patients who received standardized information (16% vs. 5%; p = 0.001). Patients in the individualized information group with a high risk of incontinence and with RARP as initial preference switched more often to other treatments than patients in intermediate/low risk of incontinence (35% vs. 9.8%; p = 0.001). Patients with a low risk of incontinence choosing RARP after individualized information were less likely to use more than one diaper a day at any time postoperative (p = 0.001) compared to men with an intermediate/high incontinence risk. Overall QoL was worse in patients with incontinence than patients with continence 6 and 12 months after RARP (respectively; p < 0.0001 and p = 0.007).Conclusion: Personalized information about the risk of incontinence after RARP makes more patients reconsidering their initial treatment preference. The CPRED correlated strongly with continence outcome after RARP and is a useful tool for shared decision‐making.
- 18 May 2021
- Published by Wiley in Neurourology and Urodynamics
- Vol. 40 (6) , 1550-1558
Individual risk prediction of urinary incontinence after prostatectomy and impact on treatment choice in patients with localized prostate cancer
Aims: Individualized information about the risk of incontinence after prostatectomy could help patients in shared decision‐making.Methods: We compared a historical control cohort (n = 254; between June 2016 and 2017) that received standardized information about the risk of incontinence after robot‐assisted radical prostatectomy (RARP) with a prospective patient cohort (n = 254; between June 2017 and May 2018) that received individualized information of the chance of recovery of incontinence within 6 months postoperatively based on the continence prediction tool (CPRED). We measured switch in treatment choice, health‐related quality of life (QoL) in both cohorts and the accuracy of the CPRED tool.Results: Patients in the individualized information group with RARP as initial preference switched more often to another treatment than patients who received standardized information (16% vs. 5%; p = 0.001). Patients in the individualized information group with a high risk of incontinence and with RARP as initial preference switched more often to other treatments than patients in intermediate/low risk of incontinence (35% vs. 9.8%; p = 0.001). Patients with a low risk of incontinence choosing RARP after individualized information were less likely to use more than one diaper a day at any time postoperative (p = 0.001) compared to men with an intermediate/high incontinence risk. Overall QoL was worse in patients with incontinence than patients with continence 6 and 12 months after RARP (respectively; p < 0.0001 and p = 0.007).Conclusion: Personalized information about the risk of incontinence after RARP makes more patients reconsidering their initial treatment preference. The CPRED correlated strongly with continence outcome after RARP and is a useful tool for shared decision‐making.
- 1 March 2017
- Published by Elsevier in European Urology Supplements
- Vol. 16 (3) , e1637-e1638
Patients’ perspectives on the risks of localized prostate cancer treatments prior to making the treatment decision
- 1 March 2017
- Published by Elsevier in European Urology Supplements
- Vol. 16 (3) , e1637-e1638
Patients’ perspectives on the risks of localized prostate cancer treatments prior to making the treatment decision